AR and neoplasm: Binding of enzalutamide to AR in the cytoplasm inhibits AR translocation into the nucleus, and in the nucleus, enzalutamide inhibits AR binding to the DNA and thereby blocks the transcription of genes associated with tumor progression and survival 18.